Seres Therapeutics (MCRB) Revenue (2016 - 2026)

Seres Therapeutics (MCRB) posted Revenue of $358000.0 for Q1 2026, down 18.26% sequentially from $438000.0 in Q4 2025.

Seres Therapeutics (MCRB) Revenue (2016 - 2026) Analysis & Trends

Seres Therapeutics has reported Revenue for 10 years, with the latest figure at $358000.0 in Q1 2026.

Quarterly Revenue changed N/A year-over-year to $358000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 million (changed N/A YoY) and the FY2025 annual result came in at $789000.0, changed N/A from the prior year.
Revenue fell to $358000.0 in Q1 2026 per MCRB's latest filing, from $438000.0 in the prior quarter.
Over five years, Revenue peaked at $126.5 million in Q2 2023 and troughed at -$126.3 million in Q4 2023.
A 4-year average of $847181.8 and a median of $522000.0 in 2023 frame the typical range for Revenue.
The widest YoY moves for Revenue: up 10300.74% in 2023, down 13049.85% in 2023.
Over 4 years, Revenue stood at $975000.0 in 2022, then sank by 13049.85% to -$126.3 million in 2023, then surged by 100.35% to $438000.0 in 2025, then declined by 18.26% to $358000.0 in 2026.
According to Business Quant data, Revenue over the past three periods registered $358000.0, $438000.0, and $351000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Revenue (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	3.33 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	4.29 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	1.52 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	145.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	1.71 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	1.29 Bn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	425.49 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	674.14 Mn
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	1.06 Bn
10	Seres Therapeutics	43.82 Mn	43.82 Mn	-	736,000.00

Download Data